Venous thromboembolism in an oncology patient

Česká verzia

Authors: A. Uhrinová; P. Gavornik; I. Vacula
Authors place of work: II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC
Published in the journal: Vnitř Lék 2009; 55(6): 599-603
Category: Case Reports

Summary

Venous thromboembolism is a common complication in many patients with different types of malignant tumors. In this paper we describe a case of a patient with cancer in remission, who developed pulmonary embolism.

Key words:
pulmonary embolism – malignancy

Zdroje

1. Trousseau A. Phlegmasia alba dolens. Clinique medicinale de l’Hotel Dieu de Paris. Paris: J-B Baillière § Fils 1865: 645–712.

2. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128: 291–302.

3. Prandoni P. Acquired risk factors for venous thromboembolism in medical patients. Pathophysiol Haemost Thromb 2006; 35: 128–132.

4. Büller HR, van Doormaal FF, van Sluis GL et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl 1): 246–254.

5. Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112–1118.

6. American College of Emergency Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected pulmonary embolism. Ann Emerg Med 2003; 41: 257–270.

7. Righini M, Perrier A, De Moerloose P et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059–1071.

8. Lee AY. Venous thromboembolism and cancer: prevention and therapy. Vnitř Lék 2006; 52 (Suppl 1): 127–131.

9. Hirmerová J. Optimální délka antikoagulační léčby po žilní tromboembolické příhodě: obecný či individualizovaný přístup? Vnitř Lék 2007; 53: 662–668.

10. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.